Pharma & Medications/Fierce Pharma

Biopharma Sector Sees $29 Billion in M&A Activity, Signaling Strong 2026 Outlook

In a significant surge of mergers and acquisitions, biopharma companies executed seven transactions totaling $29 billion in the last two weeks of March. This activity suggests a robust outlook for M&A in 2026, reinforcing the notion that the uptick observed in the fourth quarter of 2025 was not merely a temporary trend. The recent deals reflect a growing confidence among biopharma firms in pursuing strategic partnerships and consolidations to enhance their market positions and expand their portfolios. As the industry prepares for a potentially transformative year, stakeholders are closely monitoring these developments to gauge their implications for innovation and competition in the sector. The heightened M&A activity may lead to increased collaboration in research and development, ultimately benefiting patients through accelerated access to new therapies.

biopharma / mergers and acquisitions / market trends / 2026 outlook / healthcare investment

Health Tech

All →

HIMSS Global Conference Highlights Importance of Connection Amid Technological Advances

The HIMSS26 European Health Conference & Exhibition, scheduled for May 19-21, 2026, in Copenhagen, emphasizes the significance of connectivity in healthcare amidst rapid technological advancements. This three-day event will feature a comprehensive program that includes cutting-edge insights and hands-on learning opportunities, alongside continuing education (CE) accredited sessions. The conference aims to foster collaboration among healthcare professionals, technologists, and innovators to enhance patient care through technology. In addition to HIMSS26, the AI in Healthcare Forum will take place on June 25-26 in Boston, focusing on the practical applications of artificial intelligence in health and care. This forum will gather a diverse group of stakeholders, including clinicians, executives, and researchers, to explore how AI can be effectively integrated into healthcare practices. These events are crucial as they address the ongoing need for healthcare professionals to stay informed about technological innovations while maintaining strong connections within the industry. The emphasis on collaboration and education at these conferences reflects the industry's commitment to improving healthcare delivery through technology. As the healthcare landscape continues to evolve, events like HIMSS26 and the AI in Healthcare Forum will play a vital role in shaping the future of health technology and ensuring that professionals are equipped to meet the challenges ahead.

MobiHealth News · 19h ago

Disease & Epidemiology

All →

Medicare Advantage Insurers to Receive 2.5% Rate Increase in 2027 Following Policy Changes

In a significant development for the Medicare Advantage sector, the Trump administration has finalized a 2.5% increase in payment rates for 2027, a notable rise from earlier proposals. This decision comes after considerable pressure from the health insurance industry, which has been grappling with rising medical costs and has largely resisted reforms to the Medicare Advantage program. The new rates are expected to generate an additional $13 billion in revenue for insurers next year, according to estimates from the Centers for Medicare and Medicaid Services (CMS). The administration's decision also included the abandonment of a proposed risk adjustment model that would have utilized more current data for payment calculations. By scrapping this model, Medicare Advantage insurers are set to retain billions of dollars that would have otherwise been redistributed based on updated risk assessments. This move is seen as a major victory for the industry, which has consistently advocated against changes that could impact their profitability. The financial implications of this rate increase are already being felt in the stock market, with shares of major players such as UnitedHealth Group, Humana, and CVS Health rising by over 8% following the announcement. These three companies dominate the Medicare Advantage market, collectively covering nearly 60% of all enrollees in the program. As the landscape of Medicare Advantage continues to evolve, stakeholders will be closely monitoring the impact of these changes on both insurers and beneficiaries. Looking ahead, the focus will likely shift to how these increased rates will affect the quality of care provided to Medicare Advantage enrollees and whether further reforms will be proposed in the future. The ongoing dialogue between the government and the insurance industry will be crucial in shaping the future of this taxpayer-funded program.

STAT News · 19h ago

Colorado Legislation Aims to Exempt Orphan Drugs from Pricing Caps Amid Controversy

The Colorado legislature is currently considering a bill that would exempt orphan drugs from potential pricing limits set by the state's Prescription Drug Affordability Board. This marks the second attempt in two years to pass such legislation, driven by concerns that pricing caps could lead pharmaceutical companies to withdraw these essential treatments from the market, thereby limiting patient access. Orphan drugs are specifically designed to treat rare diseases, and their availability is crucial for the small patient populations they serve. Proponents of the bill argue that without these exemptions, patients may face significant barriers to accessing necessary medications. However, critics warn that the legislation could inadvertently extend to many high-revenue drugs that, while classified as orphan drugs, are used to treat more common conditions. This could lead to a situation where the intended protections for rare disease patients might instead benefit larger pharmaceutical companies, allowing them to maintain higher profit margins at the expense of broader healthcare affordability. Consumer advocates have raised alarms that such exemptions could exacerbate the financial burden on patients and taxpayers alike, as the state grapples with budgetary constraints. The ongoing debate highlights the tension between ensuring access to vital medications for rare diseases and the need for sustainable drug pricing strategies that do not compromise the healthcare system's integrity. As the bill progresses, stakeholders from both sides are closely monitoring its implications, with potential ripple effects that could influence similar legislative efforts in other states. The outcome may set a precedent for how orphan drugs are treated under pricing regulations nationwide.

STAT News · 20h ago

Medicare Advantage Payment Regulation Announcement Expected Today

The 2027 Medicare Advantage payment regulation is set to be announced today, marking a significant moment for the health insurance landscape. This regulation is mandated by law and will outline the Trump administration's approach to collaborating with the health insurance industry. The announcement is anticipated to clarify whether the administration will adopt a more stringent regulatory stance or maintain a cooperative relationship with insurers. This decision is crucial as it will influence how Medicare Advantage plans operate and how they reimburse healthcare providers, ultimately affecting millions of beneficiaries who rely on these plans for their healthcare needs. Stakeholders, including insurers, healthcare providers, and patients, are closely monitoring this announcement, as it could reshape the dynamics of Medicare Advantage for the upcoming year and beyond.

STAT News · 1d ago

Pharma & Medications

All →

Biopharma Sector Sees $29 Billion in M&A Activity, Signaling Strong 2026 Outlook

In a significant surge of mergers and acquisitions, biopharma companies executed seven transactions totaling $29 billion in the last two weeks of March. This activity suggests a robust outlook for M&A in 2026, reinforcing the notion that the uptick observed in the fourth quarter of 2025 was not merely a temporary trend. The recent deals reflect a growing confidence among biopharma firms in pursuing strategic partnerships and consolidations to enhance their market positions and expand their portfolios. As the industry prepares for a potentially transformative year, stakeholders are closely monitoring these developments to gauge their implications for innovation and competition in the sector. The heightened M&A activity may lead to increased collaboration in research and development, ultimately benefiting patients through accelerated access to new therapies.

Fierce Pharma

Clinical Research

All →

Modeling Study Reveals Effective Strategies for Community Screening of Tuberculosis

A recent modeling study published in PLoS Medicine highlights the potential of community screening to significantly reduce tuberculosis (TB) morbidity and mortality. Current TB prevention strategies have not met global targets, prompting researchers to explore various diagnostic algorithms, population coverage, and screening durations. The study utilized a deterministic compartmental model to simulate different screening approaches, including targeting symptomatic infectious TB, infectious TB, and all TB cases. The findings indicate that maximum coverage (100%) and duration (five annual rounds) could reduce symptomatic TB incidence by 26.9% with the symptomatic TB algorithm and by 74.0% with the infectious TB algorithm. However, a rebound in incidence was observed post-screening, erasing 9.8% and 15.9% of the reductions within five years, respectively. In contrast, the algorithm targeting all TB cases showed the potential for over 98% reduction with negligible rebound, although it faced challenges due to high rates of overdiagnosis. The study underscores the importance of symptom-agnostic algorithms and the need for accurate diagnostic tools to sustain the epidemiological impact of community screening. It calls for a balance between diagnostic accuracy, population coverage, and screening duration to maximize the benefits of TB screening initiatives. The researchers emphasize the necessity for further data to refine diagnostic and treatment pathways for individuals with varying disease states in community settings, aiming to enhance TB care and prevention efforts globally.

PLOS Medicine · 1d ago

Health Policy

All →

Medicare Cuts Impact Lawfully Present Immigrants, Including Seniors

In a significant policy shift, the GOP's One Big Beautiful Bill Act, signed by President Trump, will disenroll approximately 100,000 lawfully present immigrants from Medicare, effective January 4. This decision affects individuals like Rosa María Carranza, a 67-year-old child development professional who has contributed to Medicare for over two decades. The legislation specifically targets immigrants with temporary protected status, refugees, asylum-seekers, and other legal residents, arguing that taxpayer funds should not support their healthcare. This move is part of a broader Republican strategy to reduce Medicare spending and limit benefits to certain groups, despite the legal status of those affected. Carranza, who fled El Salvador during its civil war and has since built a life in the U.S., now faces uncertainty regarding her healthcare and legal residency. The changes come amid ongoing debates about immigration policy and healthcare access, with critics arguing that the disenrollment of legal residents from Medicare is unjust. The implications of this policy extend beyond healthcare, as many affected individuals fear losing their legal status and facing deportation. The Kaiser Family Foundation estimates that up to 1.4 million lawfully present immigrants could lose health insurance due to these changes, raising concerns about the broader impact on public health and community well-being. As the situation unfolds, healthcare professionals and advocates are calling for a reevaluation of policies that disproportionately affect vulnerable populations. The future of Medicare for these immigrants remains uncertain, and the potential for further restrictions looms as lawmakers continue to push for budget cuts and immigration reform.

KFF Health News · 1d ago

Post-Mastectomy Pain Syndrome: A Hidden Struggle for Breast Cancer Survivors

Post-mastectomy pain syndrome (PMPS) is a debilitating condition affecting many women after mastectomy surgeries, which are performed to treat or prevent breast cancer. This condition can manifest as severe pain, sensitivity, and discomfort, significantly impacting the quality of life for survivors. For instance, Sophia Bassan, 43, experienced excruciating pain that made daily activities unbearable, highlighting the urgent need for better awareness and treatment options. Breast cancer affects approximately 1 in 8 women in the U.S., and while mastectomies have become more common due to improved screening and treatment, the long-term consequences of these surgeries, such as PMPS, are often overlooked. Research indicates that PMPS can affect over 50% of mastectomy patients, yet it remains poorly defined and inconsistently diagnosed. Many women report feeling blindsided by chronic pain, often dismissed by healthcare providers who focus primarily on the cosmetic outcomes of surgery. This lack of recognition can lead to prolonged suffering and frustration as patients seek relief without adequate support. Experts advocate for increased research and awareness surrounding PMPS, emphasizing that successful breast cancer treatment should not only focus on survival but also on the overall well-being of patients. Legislative efforts, such as the recently introduced Advancing Women’s Health Coverage Act, aim to improve insurance coverage for complications arising from breast cancer treatments, including chronic pain. However, the path to better care is hindered by fragmented pain research and funding challenges. As the medical community grapples with these issues, it is crucial to prioritize the development of standardized diagnostic criteria and treatment protocols for PMPS, ensuring that women receive comprehensive care post-mastectomy.

KFF Health News · 1d ago

Nutrition & Prevention

All →

New Resource Guide on AI and Machine Learning for Nutrition Professionals Released by ASN-Academy Task Force

The American Society for Nutrition (ASN) has launched a comprehensive resource guide focused on the integration of artificial intelligence (AI) and machine learning in the field of nutrition. This initiative, developed by a joint task force from ASN and the ASN Academy, aims to equip nutrition professionals with the necessary tools and knowledge to leverage AI technologies in clinical care, public health, and research settings. As AI continues to transform various sectors, its application in nutrition is becoming increasingly vital for improving patient outcomes and enhancing research methodologies. The guide addresses the growing importance of AI in nutrition, highlighting its potential to streamline processes, enhance data analysis, and improve decision-making. By providing nutrition professionals with access to cutting-edge resources, the ASN aims to foster innovation and improve the quality of care delivered to patients. This resource is particularly relevant as healthcare systems worldwide are increasingly adopting AI technologies to address complex health challenges. Key stakeholders affected by this guide include dietitians, nutritionists, researchers, and public health officials who are looking to integrate AI into their practices. The guide offers insights into best practices, case studies, and practical applications of AI in nutrition, making it a valuable asset for professionals seeking to stay ahead in a rapidly evolving field. Moving forward, the ASN encourages ongoing collaboration and knowledge sharing among professionals to maximize the benefits of AI in nutrition.

Nutrition.org · 4d ago